Business
Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)
Initial TakeAim Lymphoma combination data shows anti-cancer activity, including 1 complete response and 2 partial responses, in heavily pretreated patients
About this update from Curis, Inc.
[{"type":"text","content":"Initial TakeAim Lymphoma combination data shows anti-cancer activity, including 1 complete response and 2 partial responses, in heavily pretreated patients including those with prior ibrutinib use \nLEXINGTON, Mass., May 12, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that multiple abstracts have been accepted for presentation at the upcoming European Hematology Association 2022 Hybrid Congress (EHA), which will be held virtually and in-person in Vienna on June 9-12, 2022. The abstracts include data from both the TakeAim Leukemia and TakeAim Lymphoma studies as well as other studies by Curis and independent collaborators. These planned presentations are in addition to the previously announced presentations scheduled for the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and online June 3-7, 2022.\n\n \n \n \n \n \n \n\n \n\"We are pleased that research from our lead programs will be shared with the oncology community at ASCO and EHA this year,\" said James Dentzer, Chief Executive Officer of Curis. \"We are excited to share the initial data from the TakeAim Lymphoma study investigating the use of emavusertib in combination with ibrutinib in patients with several types of Non-Hodgkin's Lymphoma. Data in the abstract indicates that the combination has shown signs of early anti-cancer activity, including in patients with prior BTK inhibitor use, and the regimen appears to be well tolerated. The data from the TakeAim Leukemia study are consistent with our findings reported in January of this year, demonstrating emavusertib's encouraging monotherapy activity in patients with R/R AML and MDS including importantly those with spliceosome and FLT3 mutations. Currently the prognosis for patients with R/R AML or MDS is grim, there are no effective therapies and new options are very much needed. In addition to data from Curis, there will be several interesting data sets from Curis's collaborators. We look forward to providing further updates at EHA and ASCO next month.\"\nBoth of the TakeAim studies are to be presented at both the ASCO and EHA meetings. In addition, at EHA Curis will present data on the development of potential biomarkers for emavusertib in AML. Fi...